Replies to post #778164 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

Gro,

Thanks for explaining the significance of the P3 for us again.






Fact ✅️:
1. The P3 is only one of the trials relevant to NWBO.
2. BP is already involved.
3. The U.S. NIH & U.S. DoD are involved.
4. NWBO owns licenses for other technologies that were not part of the P3.
5. The P3 was an exemplary trial for a challenging disease—it was clinically appropriate and compassionate.
6. FDA approved the P3 to commence, restart, and the FDA approved the trial to advance to phase 3.

https://brownneurosurgery.com/breakthrough-brain-cancer-vaccine/


Beyond the landmark DCVax-L PIII, combos are now emerging as the new focus!

DCVax-L is currently being studied in a placebo-controlled RCT that has reached PII at UCLA.

Additionally, we also have more than one DC platform to consider (aDC1 at Roswell is also being studied in combo with Keytruda).

DCVax-L Keytruda Combo:
☑️ Ongoing pembrolizumab & Hiltonol (poly-ICLC) Trial with DCVax-L
https://www.clinicaltrials.gov/study/NCT04201873


ASM June 29, 2024

NICE UK 🇬🇧 DCVax-L

AI Fact-Checking

[Roman516]

NoGrow, why you can't convince BP to be interested in NWBO and DCVax-L

Per your comments,
"Except you can't convince BP to be interested in NWBO and DCVax-L. They had years and years and have ALL passed on it. You should know that BPs don't do deals with OTC biotech drug companies -- haven't seen one in the last decade. Too many frauds in OTC world. They also can see the P3 trial history and all the protocol manipulations -- MAJOR RED FLAG. Don't be on it, it's not going to happen -- I worked with BP BizDev team and they won't even look at an OTC. ~600 major exchange biotechs to research and stay on top of. OTCs aren't worth the time."

BPs do not want NWBO and DCVax to disrupt their cash cow, IMPO.

The yearly profits for oncology drugs are significant, with projections indicating that cancer drug sales could reach $236.6 billion by 2024. Additionally, revenues from oncology drugs have increased by 96% over the past decade, growing from $52.8 billion in 2010 to $103.5 billion in 2019. This trend indicates a robust growth in the profitability of cancer therapies in recent years.

The fact that Oncologists in the US can receive up to 8% incentives from BPs to support their current SOC chemo which amounts to $20 billion a year, IMPO.

Supporting links,
https://link.springer.com/article/10.1007/s40274-021-7899-1
Per above link,
"Yearly profits for oncology drugs are significant, with projections indicating that cancer drug sales could reach $236.6 billion by 2024. Additionally, revenues from oncology drugs have increased by 96% over the past decade, growing from $52.8 billion in 2010 to $103.5 billion in 2019. This trend indicates a robust growth in the profitability of cancer therapies in recent years."

https://bigthink.com/health/cancer-drugs-most-profitable/

The fact that NWBO and DCVax has have made significant progress via UCLA and other research centers over the last few years. This supports that fact that NWBO and DCVax should be approved now. NWBO and DCVax could very well be a major disruptive factor to the present-day BPs by potentially eliminating their profits from SOC chemo, IMPO. In addition, the Oncologists invest their 8% profits into their savings accounts that are controlled by the MMs, and the MMs want to make their profits as well, IMPO. The sad news is that more and more people are dying from cancer while the greedy BPs and MMs are making huge profits, IMPO.
Why would BPs want to lose their profits to NWBO and DCVax? It is all based on greed and the evil intentions to make their profits, IMPO.

The bottom line is that NWBO and DCVax work and should be approved to help save more cancer patients and that is priceless, IMPO.

[The Danish Dude]

Flaskworks Eden dimensions

Flaskworks EDEN 2.0 – Dimensions and Cleanroom Requirements
Derived from patent WO2025106534A1 and GMP layout principles

The Flaskworks EDEN 2.0 is a compact, fully automated system for producing autologous dendritic cell vaccines. Based on patent schematics and scale references (especially Figures 9A–9C), the main console has approximate dimensions of 60–65 cm in height, 50–55 cm in width, and 70–75 cm in depth. The system includes a disposable single-patient cassette measuring 21 by 21 cm in surface area and 0.3 to 0.5 cm in thickness, with a working volume of 122 mL and a perfusion surface of 383.6 cm².

To house one EDEN unit safely in a GMP environment, a thin steel-framed enclosure would need to provide space for airflow, tubing clearance, and operator access. The recommended enclosure footprint is about 85 cm in height, 65 cm in width, and 85 cm in depth. This accounts for the unit dimensions plus 10–20 cm of structural and service buffer.

For a cleanroom installation with 12 EDEN units, each system requires approximately 1.6 meters of width and 1.4 meters of depth when spacing is included—enough to accommodate operator movement, cable routing, and GMP-required clearance. That results in a total per-unit footprint of about 2.24 square meters. Multiplying by 12 gives a base equipment area of roughly 27 square meters.

To this, an additional 10–12 square meters should be added for circulation paths and around 5–8 square meters for gowning, quality control staging, or biosafety handling zones. This yields a total recommended cleanroom area of 45 to 50 square meters, or approximately 500 to 540 square feet. A suitable layout would be two rows of six EDEN units with a central access aisle, within a room measuring roughly 7.5 by 6.5 meters.

This setup supports GMP-compliant decentralized manufacturing and aligns with MHRA modular deployment models, enabling point-of-care autologous vaccine production in NHS hospitals or satellite sites.

✅ Core Data from Advent/NWBO

• Each Grade C cleanroom under the Flaskworks model is expected to support approximately 1,000 to 1,100 patients per year, running two shifts per day

• From prior calculations, one Flaskworks EDEN unit can handle ~45–50 patients per year (single shift), or ~90–100 patients/year with two shifts.

Therefore, 1,000 patients/year ÷ 100 patients per unit = ~10 EDEN units per cleanroom.

According to this in 2023 they have 7 cleanrooms.

https://cgt.ams3.cdn.digitaloceanspaces.com/2023-Cell-and-Gene-Therapy-GMP-Manufacturing-Report.pdf

✅ Confirmed Data

• Facility: Sawston, Cambridgeshire

• Operator: Advent Bioservices (contract manufacturer for NWBO)

• Cleanroom count: 7 total cleanrooms, as listed in the report

• Cleanroom grades: Primarily Grade C, suitable for automated closed-system manufacturing (e.g. Flaskworks EDEN 2.0

Estimated Space per Cleanroom

From earlier calculation:

• Each Grade C cleanroom that supports ~10 EDEN units with 2 shifts can treat ~1,000–1,100 patients/year.

•Estimated floor space per cleanroom: ~40–45 m²

If each of the 7 cleanrooms follows this layout, the combined cleanroom area would be ~280–315 m² (3,000–3,400 ft²).

Strategic Note

• The 7 cleanrooms at Advent likely form the core of Phase 1 buildout.

• Additional cleanrooms can be added within the 88,000 ft² facility as demand scales.

• At full utilization, the site could support up to 15,000 patient doses/year, as previously projected by NWBO.


And then HyGro …. mein gott … ach du lieber.

OTCs aren't worth the time.

- HyGro

The enigma is …. it obviously IS worth your time and 20 other fudders here, devoting your lives to waste your and every one else’s lives … cancer patients litteraly.

Not only here. You are a staunch Judas coin earner on the short and distort scam hub Seeking Alpha also, where you’ve been spreading lies for many years.

As I’ve said before. The very presence and numbers of your “peer here, together with the extreme FUD activity is one of the most bullish factors and a clear sign of the threat NWBO is to your masters gameplan and it’s eventual sucess.

Regarding Flaskworks Eden.

There are only one cassette of monocytes going in and 8 doses going out.